Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Zacks
04-03

Avidity Biosciences, Inc. (RNA) shares soared 11.3% in the last trading session to close at $29.77. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.4% loss over the past four weeks.

The sudden surge in the stock price can be attributed to the positive investor mindset regarding the company's distinguished rare diseases pipeline. Avidity is currently evaluating three investigational candidates in separate mid to late-stage clinical studies for three different muscle disease indications. 

This company is expected to post quarterly loss of $0.88 per share in its upcoming report, which represents a year-over-year change of -11.4%. Revenues are expected to be $2.95 million, down 16.7% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Avidity Biosciences, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RNA going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Avidity Biosciences belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Mirum Pharmaceuticals, Inc. (MIRM), closed the last trading session 2.2% higher at $45. Over the past month, MIRM has returned -2.6%.

Mirum Pharmaceuticals' consensus EPS estimate for the upcoming report has changed -3.2% over the past month to -$0.37. Compared to the company's year-ago EPS, this represents a change of +31.5%. Mirum Pharmaceuticals currently boasts a Zacks Rank of #3 (Hold).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Avidity Biosciences, Inc. (RNA) : Free Stock Analysis Report

Mirum Pharmaceuticals, Inc. (MIRM) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10